期刊文献+

舒利迭治疗慢性阻塞性肺病的疗效观察与护理 被引量:5

暂未订购
导出
摘要 目的探讨舒利迭治疗慢性阻塞性肺病的疗效与护理效果。方法120例慢性阻塞性肺病随机分为护理干预组和对照组,两组患者均给予常规治疗,同时吸入舒利迭。对照组未给予系统的护理。结果护理干预组有效率86.7%,对照组有效率为70.0%,两组比较,经统计学分析,差异有统计学意义(P〈0.05)。护理干预组的肺功能指标FEV1、FEV1/FVC、FEV1占预计值均较对照组有显著变化,经统计学分析,差异有显著性(P〈0.05)。结论舒利迭治疗慢性阻塞性肺病稳疗效好,同时辅以一系列精心的护理措施,有效地改善了患者的肺功能。 Objective Seretide treatment of chronic obstructive pulmonary disease in the efficacy and care effect. Methods 120 palients with chronic obstructive pulmonary disease were randomly divided into intervention group and control group patients were given conventional treatment, while smoking seretide. Control group not given the system of care. The results of nursing intervention group was 86.7%, control group was 70.0%, the two groups by statistical analysis, the difference was statistically significant (P 〈0.05). Intervention group lung function indices FEV1, FEV1/FVC, FEV1 percentage of predicted value than the control group had significant change, through statistical analysis, the difference was significant (P 〈0.05). Conclusion Seretide treatment of chronic obstructive pulmonary disease stabilization is effective, supplemented by a series of well-care measures to effectively improve the patient's lung function.
作者 王莉
出处 《中国中医药咨讯》 2010年第8期183-184,共2页
关键词 慢性阻塞性肺病 舒利迭 肺功能 护理 chronic obstructive pulmonary disease Seretide lung function care
  • 相关文献

参考文献2

二级参考文献9

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8237
  • 2[2]Jones PW.Health status measurement in chronic obstructive pulmonary disease.Thorax 2001;56:880-7.
  • 3[3]Saetta M,Baraldo S,Corbino L,et al.CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease.Am J Respir Crit Care Med,1999,160:711.
  • 4[4]Shapiro SD.The macrophage in chronic obstructive pulmonary disease.Am J Respir Crit Care Med 1999,160:29-32.
  • 5[5]Bourbeau J.Effect of salmeterol/fluticasone propionate on airway inflammation in COPD:a randomised controlled trial.2007,11:938-943.
  • 6[6]Mahler DA Wire P,Horstman D,et al.Effectiveness of fluticasone propionate and salmeterol,combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.Am J Respir Crit Care Med 2002,166:1084-1091.
  • 7[7]Calverley P,Pauwels R,Vestbo J,et al.Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomised controlled trial.Lancet 2003,361:449-456.
  • 8[8]Hanania NA Darken P,Horstman D,et al.The efficacy and safety of fluticasone propionate (250 μg)/ salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD.Chest 2003; 124:834-843.
  • 9[9]Calverley PM;Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.N Engl J Med.8:775-789.

共引文献1083

同被引文献32

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部